Nombre total de rapports de communication : 0
Rapports mensuels de communications au cours des 6 derniers mois : 0
Objets | Détails | Catégories |
---|---|---|
Health
|
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies.
|
Policies or Program, Legislative Proposal, Bill or Resolution
|
Health
|
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
|
Policies or Program
|
Health
|
Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
Budget, Health
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
|
Policies or Program
|
Health, Industry, Intellectual Property
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
|
Policies or Program
|
Health, Industry
|
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
|
Policies or Program
|
Health
|
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
|
Regulation, Policies or Program
|
Adresse :
3100 Rutherford Road Suite 300
Vaughan, ON L4K 0G6
Canada
Numéro de téléphone :
866-393-1188
Adresse Web :
https://alexion.com/worldwide/canada
Kathleen Whelan, Country Lead, International Government Affairs & Policy
Alexion Pharma Canada Corp. n'est pas une coalition.
Les activités de Alexion Pharma Canada Corp. ne sont pas contrôlées ou dirigées par une autre personne morale ou physique ou par une organisation, qui est directement intéressée au résultat de cet engagement.
Alexion Pharma Canada Corp. ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement
Chris Gray | Charges publiques occupées
Cabinet d'expert-conseil : 3Sixty Public Affairs Inc.